ArticleJournal of the American College of Cardiology2008
Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection.
Article in Journal of the American College of Cardiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 70 citations in OpenAlex.
- Trial
- Antioxidative and cardioprotective effects of minocycline in ischemia/reperfusion injury in experimental model of hypertension.Molecular and cellular biochemistry · 2025Article
- Exploring molecular mechanisms of postoperative delirium through multi-omics strategies in plasma exosomes.Scientific reports · 2024Article
- Reviving the use of inhibitors of matrix metalloproteases in spinal cord injury: a case for specificity.Neural regeneration research · 2023Article
- Minocycline as heart conditioning agent in experimental type 2 diabetes mellitus - an antibacterial drug in heart protection.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling.Cardiovascular research · 2021Article
- Cardioprotective Effect of Novel Matrix Metalloproteinase Inhibitors.International journal of molecular sciences · 2020Article
- Minocycline reverses IL-17A/TRAF3IP2-mediated p38 MAPK/NF-κB/iNOS/NO-dependent cardiomyocyte contractile depression and death.Cellular signalling · 2020Article
- Minocycline protects against myocardial ischemia/reperfusion injury in rats by upregulating MCPIP1 to inhibit NF-κB activation.Acta pharmacologica Sinica · 2019Article
- Effects of tetracycline on myocardial infarct size in obese rats with chemically-induced colitis.PloS one · 2019Article
- Cardioprotection by minocycline in a rabbit model of ischemia/reperfusion injury: Detection of cell death by in vivoJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Death, near death, and an antibiotic.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Article
- Minocycline attenuates cirrhotic cardiomyopathy and portal hypertension in a rat model: Possible involvement of nitric oxide pathway.Iranian journal of basic medical sciences · 2016Article
- Minocycline attenuates cardiac dysfunction in tumor-burdened mice.Journal of molecular and cellular cardiology · 2016Article
- Co-administration of the flavanol (-)-epicatechin with doxycycline synergistically reduces infarct size in a model of ischemia reperfusion injury by inhibition of mitochondrial swelling.European journal of pharmacology · 2014Article
- Effect of tetracyclines on the development of vascular disease in veterans with acne or rosacea: a retrospective cohort study.The Journal of investigative dermatology · 2014Article
- In vivo animal stroke models: a rationale for rodent and non-human primate models.Translational stroke research · 2013Review
- Minocycline: far beyond an antibiotic.British journal of pharmacology · 2013Review
- Experimental doxycycline overdose in rats causes cardiomyopathy.International journal of experimental pathology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesThe ability of minocycline to be transported into cardiac cells, concentrate in normal and ischemic myocardium, and act as a cardioprotector in vivo was examined. We also determined minocycline's capacity to act as a reducer of myocardial oxidative stress and matrix metalloproteinase (MMP) activity.
backgroundThe identification of compounds with the potential to reduce myocardial ischemic injury is of great interest. Tetracyclines are antibiotics with pleiotropic cytoprotective properties that accumulate in normal and diseased tissues. Minocycline is highly lipophilic and has shown promise as a possible cardioprotector. However, minocycline's potential as an in vivo cardioprotector as well as the means by which this action is attained are not well understood.
methodsRats were subjected to 45 min of ischemia and 48 h of reperfusion. Animals were treated 48 h before and 48 h after thoracotomy with either vehicle or 50 mg/kg/day minocycline. Tissue samples were used for biochemical assays and cultured cardiac cells for minocycline uptake experiments.
resultsMinocycline significantly reduced infarct size (approximately 33%), tissue MMP-9 activity, and oxidative stress. Minocycline was concentrated approximately 24-fold in normal (0.5 mmol/l) and approximately 50-fold in ischemic regions (1.1 mmol/l) versus blood. Neonatal rat cardiac fibroblasts, myocytes, and adult fibroblasts demonstrated a time- and temperature-dependent uptake of minocycline to levels that approximate those of normal myocardium.
conclusionsGiven the high intracellular levels observed and results from the assessment of in vitro antioxidant and MMP inhibitor capacities, it is likely that minocycline acts to limit myocardial ischemic injury via mass action effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.